PTC Therapeutics (PTCT) Competitors $47.21 -1.40 (-2.88%) (As of 01:27 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PTCT vs. SMMT, GMAB, RDY, SRPT, CTLT, PCVX, QGEN, ITCI, ROIV, and ASNDShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Summit Therapeutics (NASDAQ:SMMT) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends. Do institutionals and insiders hold more shares of SMMT or PTCT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, SMMT or PTCT? Summit Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K19,805.75-$614.93M-$0.28-67.14PTC Therapeutics$900.66M4.12-$626.60M-$5.94-8.10 Is SMMT or PTCT more profitable? Summit Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% PTC Therapeutics -50.32%N/A -16.44% Do analysts recommend SMMT or PTCT? Summit Therapeutics currently has a consensus price target of $33.33, suggesting a potential upside of 77.30%. PTC Therapeutics has a consensus price target of $54.08, suggesting a potential upside of 12.33%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83PTC Therapeutics 3 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47 Does the MarketBeat Community favor SMMT or PTCT? PTC Therapeutics received 260 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 61.92% of users gave PTC Therapeutics an outperform vote while only 58.22% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30158.22% Underperform Votes21641.78% PTC TherapeuticsOutperform Votes56161.92% Underperform Votes34538.08% Which has more risk and volatility, SMMT or PTCT? Summit Therapeutics has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Does the media favor SMMT or PTCT? In the previous week, Summit Therapeutics had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 8 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Summit Therapeutics' score of 0.91 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPTC Therapeutics beats Summit Therapeutics on 10 of the 19 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.75B$6.40B$4.96B$9.33BDividend YieldN/A3.06%4.84%4.03%P/E Ratio-8.1810.62108.0817.62Price / Sales4.16301.461,290.1382.67Price / Cash19.1456.6541.1638.32Price / Book-4.485.414.844.93Net Income-$626.60M$150.96M$117.44M$225.47M7 Day Performance-2.76%-5.51%16.08%-0.01%1 Month Performance23.91%0.26%18.97%5.92%1 Year Performance71.22%15.31%37.24%22.97% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics4.0058 of 5 stars$47.21-2.9%$54.08+14.5%+71.2%$3.64B$900.66M-7.951,410Positive NewsSMMTSummit Therapeutics3.3876 of 5 stars$18.71+4.9%$33.33+78.2%+629.7%$13.80B$700,000.00-63.68105GMABGenmab A/S4.3626 of 5 stars$20.14-0.1%$45.20+124.4%-35.1%$13.33B$19.84B19.582,204Short Interest ↓High Trading VolumeRDYDr. Reddy's Laboratories1.8595 of 5 stars$14.77+2.1%$17.00+15.1%+10.3%$12.33B$299.87B22.9527,048SRPTSarepta Therapeutics4.9106 of 5 stars$126.12+1.9%$178.71+41.7%+36.3%$12.05B$1.64B98.971,314Insider TradePositive NewsCTLTCatalent2.7682 of 5 stars$63.48+0.7%$63.40-0.1%+53.0%$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.8036 of 5 stars$90.42+3.1%$147.50+63.1%+47.8%$11.27BN/A-19.07160Positive NewsQGENQiagen4.2447 of 5 stars$45.44+0.1%$51.15+12.6%+3.7%$10.37B$1.97B117.035,967ITCIIntra-Cellular Therapies4.1886 of 5 stars$84.31+1.5%$97.23+15.3%+30.1%$8.94B$612.78M-95.91560ROIVRoivant Sciences2.6739 of 5 stars$12.13+2.4%$17.93+47.8%+8.4%$8.83B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2177 of 5 stars$136.47+5.1%$191.77+40.5%+12.9%$8.28B$327.43M-16.52640Short Interest ↑News CoveragePositive News Related Companies and Tools Related Companies SMMT Alternatives GMAB Alternatives RDY Alternatives SRPT Alternatives CTLT Alternatives PCVX Alternatives QGEN Alternatives ITCI Alternatives ROIV Alternatives ASND Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTCT) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
